Alentia Therapeutics

Alentis Therapeutics is a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting Claudin-1 (CLDN1) for the treatment of fibrosis and various cancers. Based in Basel, Switzerland, the company leverages a deep understanding of CLDN1 biology, a protein that plays a critical role in tight junction formation and is highly overexpressed in fibrotic tissues and specific tumor types. Their lead programs include ALE-F02, an antibody designed to reverse organ fibrosis, and ALE-C04, a first-in-class antibody for the treatment of CLDN1-positive squamous cell carcinomas. Alentis is also expanding its pipeline with Claudin-1 targeted antibody-drug conjugates (ADCs) to address unmet needs in oncology. The company is backed by a strong syndicate of international life science investors, including Novo Holdings and RA Capital.